Pharmstandard-UfaVITA is going to produce hemophilia therapies


Igor Komarov, the Plenipotentiary representative of the President of Russia in the Volga Federal District and Radiy Khabirov, the head of Bashkortostan, visited the production workshops of Pharmstandard-UfaVITA. This is reported by Bashinform.

According to Nail Nizamutdinov, the general director of the enterprise, since December 2020, the facility has been producing Sputnik V vaccine, and Sputnik Lite since 2021. This made it possible to achieve a 259.7% increase in the industrial production index by the end of last year. The cost of shipped products amounted to 69.1 billion rubles.

In 2021, a workshop for the production of medicines in the form of tablets with a capacity of 3 billion units per year was also launched at the Pharmstandart plant in Ufa.  The company invested 1.53 billion rubles in the production facility. The manufacturer previously invested 918 million rubles in a line for the production of injection solutions in polymer vials and plastic ampoules. This enabled the company to hire 125 new specialists.

In addition, Pharmstandard-UfaVITA launched new water treatment facilities in the first quarter of 2022. The company spent 257.7 million rubles on the modernization of the system.

In the third quarter, the construction of a workshop for the production of blood clotting factor VIII, for hemophilia patients, should be completed. This drug is not produced there yet: the line will be launched in 2023. The project costs 1.58 billion rubles. 80 new jobs will be created.